Juno Therapeutics (JUNO) CEO Bishop: Second JCAR015 Patient with Brain Swelling has Died - Conf. call

November 23, 2016 8:44 AM EST

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Juno Therapeutics (NASDAQ: JUNO) CEO Hans Bishop said that the second JCAR015 patient with brain swelling has died, according to the company's conference call on Wednesday. Patients who died were treated last week, the CEO noted.

The company has treated 12 patients since restarting the ROCKET trial of JCAR015.

Bishop said that the company hopes to give an update on JCAR015 at ASH 2016.

Earlier, Juno said in a press release: One patient died and as of last night the other is not expected to recover. For more on the JCAR015 trial, click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

FDA, Management Comments, Trader Talk

Add Your Comment